Altogether, blocking ABCC4 function by a specific inhibitor exerts a protective effect on lipid metabolism by enhancing LDLR availability and mitigating hypercholesterolemia, highlighting ABCC4 as a promising therapeutic target. Here, LDLR is linked to familial hypercholesterolemia.